Keir HR[au] - Search Results

Year	Number of Results
2017	3
2018	2
2019	7
2020	6
2021	15
2022	6

1

Integrative microbiomics in bronchiectasis exacerbations.

Mac Aogáin M, Narayana JK, Tiew PY, Ali NABM, Yong VFL, Jaggi TK, Lim AYH, Keir HR, Dicker AJ, Thng KX, Tsang A, Ivan FX, Poh ME, Oriano M, Aliberti S, Blasi F, Low TB, Ong TH, Oliver B, Giam YH, Tee A, Koh MS, Abisheganaden JA, Tsaneva-Atanasova K, Chalmers JD, Chotirmall SH. Mac Aogáin M, et al. Among authors: keir hr. Nat Med. 2021 Apr;27(4):688-699. doi: 10.1038/s41591-021-01289-7. Epub 2021 Apr 5. Nat Med. 2021. PMID: 33820995

2

The sputum microbiome, airway inflammation, and mortality in chronic obstructive pulmonary disease.

Dicker AJ, Huang JTJ, Lonergan M, Keir HR, Fong CJ, Tan B, Cassidy AJ, Finch S, Mullerova H, Miller BE, Tal-Singer R, Chalmers JD. Dicker AJ, et al. Among authors: keir hr. J Allergy Clin Immunol. 2021 Jan;147(1):158-167. doi: 10.1016/j.jaci.2020.02.040. Epub 2020 Apr 28. J Allergy Clin Immunol. 2021. PMID: 32353489

3

The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study.

Dicker AJ, Lonergan M, Keir HR, Smith AH, Pollock J, Finch S, Cassidy AJ, Huang JTJ, Chalmers JD. Dicker AJ, et al. Among authors: keir hr. Lancet Respir Med. 2021 Aug;9(8):885-896. doi: 10.1016/S2213-2600(20)30557-9. Epub 2021 May 4. Lancet Respir Med. 2021. PMID: 33961805

4

Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort study.

Keir HR, Shoemark A, Dicker AJ, Perea L, Pollock J, Giam YH, Suarez-Cuartin G, Crichton ML, Lonergan M, Oriano M, Cant E, Einarsson GG, Furrie E, Elborn JS, Fong CJ, Finch S, Rogers GB, Blasi F, Sibila O, Aliberti S, Simpson JL, Huang JTJ, Chalmers JD. Keir HR, et al. Lancet Respir Med. 2021 Aug;9(8):873-884. doi: 10.1016/S2213-2600(20)30504-X. Epub 2021 Feb 17. Lancet Respir Med. 2021. PMID: 33609487

5

Pathophysiology of Bronchiectasis.

Keir HR, Chalmers JD. Keir HR, et al. Semin Respir Crit Care Med. 2021 Aug;42(4):499-512. doi: 10.1055/s-0041-1730891. Epub 2021 Jul 14. Semin Respir Crit Care Med. 2021. PMID: 34261175

6

Characterization of Eosinophilic Bronchiectasis: A European Multicohort Study.

Shoemark A, Shteinberg M, De Soyza A, Haworth CS, Richardson H, Gao Y, Perea L, Dicker AJ, Goeminne PC, Cant E, Polverino E, Altenburg J, Keir HR, Loebinger MR, Blasi F, Welte T, Sibila O, Aliberti S, Chalmers JD. Shoemark A, et al. Among authors: keir hr. Am J Respir Crit Care Med. 2022 Apr 15;205(8):894-902. doi: 10.1164/rccm.202108-1889OC. Am J Respir Crit Care Med. 2022. PMID: 35050830

7

Inhaled Corticosteroids and the Lung Microbiome in COPD.

Keir HR, Contoli M, Chalmers JD. Keir HR, et al. Biomedicines. 2021 Sep 24;9(10):1312. doi: 10.3390/biomedicines9101312. Biomedicines. 2021. PMID: 34680429 Free PMC article. Review.

8

Less is more? Antibiotic treatment duration for exacerbations of bronchiectasis.

Chalmers JD, Keir HR. Chalmers JD, et al. Among authors: keir hr. Eur Respir J. 2021 Dec 16;58(6):2101416. doi: 10.1183/13993003.01416-2021. Print 2021 Dec. Eur Respir J. 2021. PMID: 34916253 No abstract available.

9

IL-6 trans-signalling: how Haemophilus surfs the NET to amplify inflammation in COPD.

Keir HR, Chalmers JD. Keir HR, et al. Eur Respir J. 2021 Oct 14;58(4):2102143. doi: 10.1183/13993003.02143-2021. Print 2021 Oct. Eur Respir J. 2021. PMID: 34649972 No abstract available.

10

SPLUNC1 is a novel marker of disease severity and airway infection in bronchiectasis.

Keir HR, Shoemark A, Huang JTJ, Chalmers JD. Keir HR, et al. Eur Respir J. 2021 Nov 11;58(5):2101840. doi: 10.1183/13993003.01840-2021. Print 2021 Nov. Eur Respir J. 2021. PMID: 34413156 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results